MAGEA3 and lung carcinoma: Classical T cell-based approaches such as tumor vaccination seem more appropriate, however, two large phase III vaccination studies using recombinant proteins of CTA MAGE-A3 for lung cancer and melanoma, the MAGRIT and DERMA trials, have recently failed.